H.C. Wainwright upgraded UroGen Pharma (URGN) to Buy from Neutral with a $50 price target The company announced that the FDA had approved Zusduri, the first and only FDA-approved medication for adults with recurrent low-grade, intermediate-risk non-muscle-invasive bladder cancer, the analyst tells investors in a research note. The firm says the approval “represents a highly welcome result and a positive surprise” in the wake of last month’s negative FDA panel vote.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- UroGen Pharma price target raised to $16 from $3 at Goldman Sachs
- UroGen Pharma price target raised to $31 from $10 at Oppenheimer
- UroGen Pharma price target raised to $47 from $23 at Scotiabank
- FDA Approves Urogen Pharma’s ZUSDURI for Bladder Cancer
- UroGen Pharma price target raised to $30 from $15 at Guggenheim